Overview
Lobbying Costs
17,500€
Financial year: Jan 2020 - Dec 2020
Lobbyists (Full time equivalent)
1 Fte (4)
Lobbyists with EP accreditation
0
High-level Commission meetings
9
Lobbying Costs over the years
-
Info
CureVac AG
EU Transparency Register
798772637872-28 First registered on 17 Apr 2020
Goals / Remit
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. Based on its proprietary technology, the Company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered in Tübingen, Germany, and employs more than 600 people at its sites in Tübingen, Frankfurt, and Boston, USA.
Main EU files targeted
Current activities:
- Interactions with European Commission and EIB to financially support upscaling manufacturing capacity for mRNA drugs – inter alia for vaccines.
- Interactions regarding delivery of COVID-19 vaccine (CVnCoV) doses.
- Interactions with European Commission covering pandemic preparedness.Address
Head Office
Friedrich-Miescher-Str. 15
Tübingen 72076
GERMANY -
People
Total lobbyists declared
4
Employment time Lobbyists 25% 4 Lobbyists (Full time equivalent)
1
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
Not applicable
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
- Vaccines Europe
- Verband Forschender Arzneimittelhersteller e.V.
- Bio Deutschland e.V.
- Wissensfabrik - Unternehmen für Deutschland e.V.
- Verein zur Förderung der Biotechnologie und Medizintechnik e. V.
- Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
- Verband der Chemischen Industrie e. V.
- German Quality Management Association e.V.
- Deutsche Gesellschaft für Regulatory Affairs e.V.Member organisations
Not applicable
-
Financial Data
Closed financial year
Jan 2020 - Dec 2020
Lobbying costs for closed financial year
17,500€
Other financial info
Details on Procurement: CureVac received 450,000,000 € upfront payment from the European Commission as part of the Advance Purchase Agreement for CureVac´s mRNA-based COVID-19 vaccine candidate CVnCoV.
Link: https://www.curevac.com/en/2020/11/16/european-commission-announces-that-tomorrow-it-will-authorize-the-agreement-with-curevac-for-the-supply-of-up-to-405-million-doses-of-mrna-based-covid-19-vaccine-candidate-cvncov/
Additionally, CureVac received a 25,000,000 € loan from the European Investment Bank.
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
Not applicable
Other activities
Not applicable
Meetings
Meetings
9 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 30 Nov 2022 Location Brussels Subject Medicines manufacturing and pandemic preparedness Cabinet Cabinet of Commissioner Thierry Breton Portfolio Internal Market Attending - Maurits-Jan Prinz (Cabinet member)
-
Date 02 Mar 2021 Location Videoconference Subject Vaccine production Cabinet Cabinet of Commissioner Thierry Breton Portfolio Internal Market Attending - Thierry Breton (Commissioner)
Other Lobbyists -
Date 08 Feb 2021 Location webex Subject meeting with Curevac - vaccines DG Health and Food Safety Attending - Sandra Gallina (Director-General)
-
Date 31 Jan 2021 Location Videoconference Subject Meeting with CEOs of the pharmaceutical companies with which the Commission has signed Advance Purchase Agreements Cabinet Cabinet of President Ursula von der Leyen Portfolio President Attending - Ursula von der Leyen (President)
Other Lobbyists -
Date 06 Jul 2020 Location Video-conferencing Subject CureVac Signature Cabinet Cabinet of Commissioner Mariya Gabriel Portfolio Digital Economy and Society Attending - Mariya Gabriel (Commissioner)
-
Date 06 Jul 2020 Location Video-conferencing Subject CureVac Signature Cabinet Cabinet of Commissioner Mariya Gabriel Portfolio Innovation and Youth Attending - Mariya Gabriel (Commissioner)
-
Date 16 Mar 2020 Location video-conferencing Subject COVID-19 Cabinet Cabinet of Commissioner Mariya Gabriel Portfolio Digital Economy and Society Attending - Mariya Gabriel (Commissioner)
-
Date 16 Mar 2020 Location Videoconference Subject Videconderence with CureVac representatives on COVID-19 Cabinet Cabinet of President Ursula von der Leyen Portfolio President Attending - Ursula von der Leyen (President)
-
Date 16 Mar 2020 Location video-conferencing Subject COVID-19 Cabinet Cabinet of Commissioner Mariya Gabriel Portfolio Innovation and Youth Attending - Mariya Gabriel (Commissioner)